In HCC, sorafenib aggravates microenvironmental hypoxia while exerting anti-tumor effects and then induces the enhancement of CSC properties by activating HIF-1α, which leads to drug resistance5,6. Here, HIF1A is linked to hepatocellular carcinoma.